AKBA Akebia Therapeutics, Inc.
P/E
--
Forward P/E
28.74
Price/Sales
0.74
Beta
0.18
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Akebia Therapeutics third quarter 2026 revenue misses as Vafseo inventory adjustments offset patient growth
Akebia reported third quarter 2026 results that fell short of analyst estimates on both top and bottom lines, as a steep decline in Auryxia sales more than...
Akebia Therapeutics Q3 2026 Earnings Preview: What Analysts Expect on November 05, 2026
Analysts expect Akebia Therapeutics to report a Q3 2026 loss of $0.04 per share on revenue of $46.94 million, as the stock trades at approximately $0.71, well...
Akebia Therapeutics Receives Nasdaq Notice for Non-Compliance with Minimum Bid Price Rule
Akebia Therapeutics, Inc. (AKBA) announced it received a deficiency notice from the Nasdaq Stock Market on October 21, 2026. The notice was issued because the...